Search

Displaying results 1211 - 1220 of 2674 in total
  1. Target

    Low affinity immunoglobulin gamma Fc region receptor III-B

    go.drugbank.com/bio_entities/BE0000901
    TargetHumans

    Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG.

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-BSynonyms: IgG Fc receptor III-1
  2. Target

    Low affinity immunoglobulin gamma Fc region receptor II-b

    go.drugbank.com/bio_entities/BE0002099
    TargetHumans

    Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. … Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor.

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-bSynonyms: IgG Fc receptor II-b
  3. Target

    Transient receptor potential cation channel subfamily V member 6

    go.drugbank.com/bio_entities/BE0005102
    TransporterTargetHumans

    Calcium selective cation channel that mediates Ca(2+) uptake in various tissues, including the intestine (PubMed:11097838, PubMed:11248124, PubMed:11278579, PubMed:15184369, PubMed:23612980, PubMed:29258289). Important for normal Ca(2+) ...

    Polypeptides: Transient receptor potential cation channel subfamily V member 6
  4. Drug

    Gluconic Acid

    go.drugbank.com/drugs/DB13180
    ApprovedInvestigational

    Commonly found in salts with sodium and calcium. Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.

  5. Drug

    Pioglitazone

    go.drugbank.com/drugs/DB01132
    ApprovedInvestigational

    [A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart … and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma

    Categories: Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity
  6. Drug

    Eugenol

    go.drugbank.com/drugs/DB09086
    ApprovedInvestigational

    Although not currently available in any FDA-approved products (including OTC), eugenol has been found to have anti-inflammatory, neuroprotective, antipyretic, antioxidant, antifungal and analgesic properties

  7. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … [L54638] Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR).

  8. Target

    Frataxin, mitochondrial

    go.drugbank.com/bio_entities/BE0008991
    TargetHumans

    Functions as an activator of persulfide transfer to the scaffoding protein ISCU as component of the core iron-sulfur cluster (ISC) assembly complex and participates to the [2Fe-2S] cluster assembly (PubMed:12785837, PubMed:24971490). Acc...

    Synonyms: FRDA
  9. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    [A179209] Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- … Alpelisib was granted FDA approval on 24 May 2019.

  10. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational